OBLN - オバロン・セラピュ―ティクス (Obalon Therapeutics Inc.)

OBLNのニュース

   The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation  2020/04/07 11:55:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs April 6.) Forty Seven Inc (NASDAQ: FTSV ) Masimo Corporation (NASDAQ: MASI ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) Down In The Dumps (Biotech stocks that hit 52-week lows April 6) BIOLASE Inc (NASDAQ: BIOL ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Global Cord Blood Corp (NYSE: CO ) ImmuCell Corporation (NASDAQ: ICCC ) IMMURON LTD/S ADR (NASDAQ: IMRN ) Menlo Therapeutics Inc (NASDAQ: MNLO ) (flunked two late-stage studies that evaluated oral serlopitant for treating pruritus associated with prurigo nodularis) Merus NV (NASDAQ: MRUS ) Millendo Therapeutics Inc (NASDAQ: MLND ) (said it is discontinuing development of livoletide as a potential treatment for Prader-Willi syndrome following failed Phase 2b study) Obalon Therapeutics Inc (NASDAQ: OBLN ) Quest Diagnostics Inc (NYSE: DGX ) (said it has performed 550,000 COVID-19 tests) Second Sight Medical Products Inc (NASDAQ: EYES ) Stocks In Focus Sanofi, Regeneron Finalize Previously Announced Praluent Restructuring Sanofi SA (NASDAQ: SNY ) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) announced they have finalized the planned restructuring related to cholesterol drug Praluent.
   Obalon +8.6% on new stock purchase agreement  2020/02/07 23:27:06 Seeking Alpha
Obalon Therapeutics (NASDAQ:OBLN) is up 8.6% postmarket after entering into a new stock purchase agreement and registration rights agreement with Lincoln P
   Is OBALON THERPTCS (OBLN) Stock Outpacing Its Medical Peers This Year?  2020/01/24 16:30:10 Zacks Investment Research
Is (OBLN) Outperforming Other Medical Stocks This Year?
   Obalon Therapeutics Inc (NASDAQ:OBLN) CEO Buys $107,900.00 in Stock  2019/11/17 12:38:32 Modern Readers
Obalon Therapeutics Inc (NASDAQ:OBLN) CEO William J. Plovanic acquired 65,000 shares of the stock in a transaction dated Tuesday, November 12th. The shares were purchased at an average cost of $1.66 per share, with a total value of $107,900.00. Following the completion of the purchase, the chief executive officer now owns 106,806 shares of the […]
   OBALON THERPTCS (OBLN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release  2019/11/01 14:30:29 Zacks Investment Research
OBALON THERPTCS (OBLN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation  2020/04/07 11:55:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs April 6.) Forty Seven Inc (NASDAQ: FTSV ) Masimo Corporation (NASDAQ: MASI ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) Down In The Dumps (Biotech stocks that hit 52-week lows April 6) BIOLASE Inc (NASDAQ: BIOL ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Global Cord Blood Corp (NYSE: CO ) ImmuCell Corporation (NASDAQ: ICCC ) IMMURON LTD/S ADR (NASDAQ: IMRN ) Menlo Therapeutics Inc (NASDAQ: MNLO ) (flunked two late-stage studies that evaluated oral serlopitant for treating pruritus associated with prurigo nodularis) Merus NV (NASDAQ: MRUS ) Millendo Therapeutics Inc (NASDAQ: MLND ) (said it is discontinuing development of livoletide as a potential treatment for Prader-Willi syndrome following failed Phase 2b study) Obalon Therapeutics Inc (NASDAQ: OBLN ) Quest Diagnostics Inc (NYSE: DGX ) (said it has performed 550,000 COVID-19 tests) Second Sight Medical Products Inc (NASDAQ: EYES ) Stocks In Focus Sanofi, Regeneron Finalize Previously Announced Praluent Restructuring Sanofi SA (NASDAQ: SNY ) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) announced they have finalized the planned restructuring related to cholesterol drug Praluent.
   Obalon +8.6% on new stock purchase agreement  2020/02/07 23:27:06 Seeking Alpha
Obalon Therapeutics (NASDAQ:OBLN) is up 8.6% postmarket after entering into a new stock purchase agreement and registration rights agreement with Lincoln P
   Is OBALON THERPTCS (OBLN) Stock Outpacing Its Medical Peers This Year?  2020/01/24 16:30:10 Zacks Investment Research
Is (OBLN) Outperforming Other Medical Stocks This Year?
   Obalon Therapeutics Inc (NASDAQ:OBLN) CEO Buys $107,900.00 in Stock  2019/11/17 12:38:32 Modern Readers
Obalon Therapeutics Inc (NASDAQ:OBLN) CEO William J. Plovanic acquired 65,000 shares of the stock in a transaction dated Tuesday, November 12th. The shares were purchased at an average cost of $1.66 per share, with a total value of $107,900.00. Following the completion of the purchase, the chief executive officer now owns 106,806 shares of the […]
   OBALON THERPTCS (OBLN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release  2019/11/01 14:30:29 Zacks Investment Research
OBALON THERPTCS (OBLN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation  2020/04/07 11:55:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs April 6.) Forty Seven Inc (NASDAQ: FTSV ) Masimo Corporation (NASDAQ: MASI ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) Down In The Dumps (Biotech stocks that hit 52-week lows April 6) BIOLASE Inc (NASDAQ: BIOL ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Global Cord Blood Corp (NYSE: CO ) ImmuCell Corporation (NASDAQ: ICCC ) IMMURON LTD/S ADR (NASDAQ: IMRN ) Menlo Therapeutics Inc (NASDAQ: MNLO ) (flunked two late-stage studies that evaluated oral serlopitant for treating pruritus associated with prurigo nodularis) Merus NV (NASDAQ: MRUS ) Millendo Therapeutics Inc (NASDAQ: MLND ) (said it is discontinuing development of livoletide as a potential treatment for Prader-Willi syndrome following failed Phase 2b study) Obalon Therapeutics Inc (NASDAQ: OBLN ) Quest Diagnostics Inc (NYSE: DGX ) (said it has performed 550,000 COVID-19 tests) Second Sight Medical Products Inc (NASDAQ: EYES ) Stocks In Focus Sanofi, Regeneron Finalize Previously Announced Praluent Restructuring Sanofi SA (NASDAQ: SNY ) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) announced they have finalized the planned restructuring related to cholesterol drug Praluent.
   Obalon +8.6% on new stock purchase agreement  2020/02/07 23:27:06 Seeking Alpha
Obalon Therapeutics (NASDAQ:OBLN) is up 8.6% postmarket after entering into a new stock purchase agreement and registration rights agreement with Lincoln P
   Is OBALON THERPTCS (OBLN) Stock Outpacing Its Medical Peers This Year?  2020/01/24 16:30:10 Zacks Investment Research
Is (OBLN) Outperforming Other Medical Stocks This Year?
   Obalon Therapeutics Inc (NASDAQ:OBLN) CEO Buys $107,900.00 in Stock  2019/11/17 12:38:32 Modern Readers
Obalon Therapeutics Inc (NASDAQ:OBLN) CEO William J. Plovanic acquired 65,000 shares of the stock in a transaction dated Tuesday, November 12th. The shares were purchased at an average cost of $1.66 per share, with a total value of $107,900.00. Following the completion of the purchase, the chief executive officer now owns 106,806 shares of the […]
   OBALON THERPTCS (OBLN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release  2019/11/01 14:30:29 Zacks Investment Research
OBALON THERPTCS (OBLN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

calendar